Mobocertinib

Targeted TherapyApproved for: NSCLCBiomarker: EGFR Exon20 Insertion Mobocertinib (EXKIVITY) is the first oral therapy specifically designed for patients with EGFR Exon20 insertion+ NSCLC Related Research News Novel drug shows promise in early-stage ROS1 clinical trialsGSK hits go on pivotal...
|
January 5, 2022
|